(Q37546027)

20 August 2017

1 reference

title

Cervical cancer therapy: current, future and anti-angiogensis targeted treatment (English)

1 reference

20 August 2017

main subject

cervix uterine cancer

1 reference

2

Bradley J Monk

1 reference

20 August 2017

Lyndsay J Willmott

1

1 reference

20 August 2017

publication date

1 July 2009

1 reference

Expert Review of Anticancer Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

9

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

895-903

1 reference

Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial

20 August 2017

cites work

1 reference

Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer

21 January 2018

1 reference

Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions

21 January 2018

1 reference

Pelvic exenteration for gynaecological tumours: achievements and unanswered questions

21 January 2018

1 reference

Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies.

21 January 2018

1 reference

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

21 January 2018

1 reference

Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma

21 January 2018

1 reference

HIFs and tumors--causes and consequences

21 January 2018

1 reference

Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.

21 January 2018

1 reference

Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells

21 January 2018

1 reference

21 January 2018

1 reference

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.

21 January 2018

1 reference

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

21 January 2018

1 reference

Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies

21 January 2018

1 reference

Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells

21 January 2018

1 reference

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1

21 January 2018

1 reference

Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets

21 January 2018

1 reference

Breast tumour angiogenesis

21 January 2018

1 reference

Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

21 January 2018

1 reference

Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI.

21 January 2018

1 reference

Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer

21 January 2018

1 reference

Vascular endothelial growth factor serum concentrations in ovarian cancer.

21 January 2018

1 reference

A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer

21 January 2018

1 reference

Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer.

21 January 2018

1 reference

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer

21 January 2018

1 reference

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

21 January 2018

1 reference

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

Update on novel therapeutic agents for cervical cancer

21 January 2018

1 reference

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.09.58

1 reference

20 August 2017

1 reference